Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2026Drug Design Development and TherapyOpen Access

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXiao-Dong WangHangzhou First People's HospitalCSChunhui ShouHangzhou First People's HospitalSCSheng-Chuan ChenHangzhou First People's Hospital

Discussion

Loading...

Member takes

Implication

Review discusses challenges of drug resistance in Advanced GIST, suggesting new treatment approaches.

Key Points

  • This review aims to highlight the evolution of targeted therapy for advanced gastrointestinal stromal tumors (GIST) and address ongoing clinical challenges.
  • Discussed current standard drug treatment strategies for advanced GIST.
  • Explored sequential TKI therapy and mechanisms of drug resistance.
  • Investigated future directions for GIST drug development.
  • Highlighted high rates of drug resistance among patients undergoing TKI therapy.
  • Identified intratumoral heterogeneity as a significant barrier to effective treatment.
  • Recommended mutation-stratified therapeutic sequencing and ctDNA-guided monitoring.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69cd7a4e5652765b073a752bhttps://doi.org/10.2147/dddt.s594043
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MicroRNA expression signature in gastrointestinal stromal tumour & their molecular & histological features2024 · 3 citations
  2. 2Hypoxia-inducible Factor-1α is Associated with Risk of Aggressive Behavior and Tumor Angiogenesis in Gastrointestinal Stromal Tumor2005 · 72 citations
  3. 3Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors1998 · 4,512 citations
  4. 4Gastric stromal tumors Reappraisal of histogenesis1983 · 1,050 citations
  5. 5Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial2023 · 338 citations